Clinical trial NCT01000961: Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
Official title: A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Cystinosis
Keywords: cystinosis
cysteamine
inheritable disease
orphan disease
CTNS protein, human
metabolic disease
nephropathic cystinosis
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2009-10-23
Enrollment: 43
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Cystinosis is an inherited disease that if untreated, results in kidney failure as early as the first decade of life. The current marketed therapy is Cystagon® (cysteamine bitartrate) which must be taken every six hours for the rest of the patient's life to prevent complications of cystinosis. RP103 is a formulation of cysteamine bitartrate that is being studied to see if it may be able to be given less frequently, once every 12 hours, and have similar results to four times a day Cystagon®.

Detailed description: This is a multi-center, open-label, randomized, cross-over study to determine whether steady-state, twice a day treatment with Cysteamine Bitartrate Delayed-release Capsules(RP103) results in comparable depletion of white blood cell (WBC) cystine levels compared to the existing four times a day cysteamine treatment. It will involve up to 20 clinic visits plus intermittent home use of the RP103. Most of these clinic visits occur in clusters of 3-4 consecutive days. Eligible patients will be offered enrollment into a long-term follow up study.

Study with completed results acquired from Horizon in 2024.

Eligibility criteria: Inclusion Criteria:

* Male and female subjects must have nephropathic cystinosis.
* Subjects must be on a stable dose of Cystagon® sufficient to maintain their white blood cell (WBC) cystine level at ≤ 1.0 nmol/half-cystine/mg protein.
* Subjects must be able to swallow their typically administered Cystagon® capsule with the capsule intact.
* Within the last 6 months, no clinically significant change in liver function \[i.e., ALT, AST, total bilirubin\] and renal function \[i.e., estimated GFR\] at Screening as determined by the Investigator.
* Subjects with an estimated GFR (corrected for body surface area) \> 30 mL/min/1.73m2.
* Sexually active female subjects of childbearing potential (i.e., not surgically sterile \[tubal ligation, hysterectomy, or bilateral oophorectomy\] or at least 2 years naturally postmenopausal) must agree to utilize the same acceptable form of contraception from Screening through completion of the study.
* Subjects must be willing and able to comply with the study restrictions and requirements.
* Subjects or their or their parent or guardian must provide written informed consent and assent (where applicable) prior to participation in the study.

Exclusion Criteria:

* Subject's age \< 6 years old or subject's weight \< 21 kg.
* Subjects with a known history, currently of the following conditions or other health issues that make it, in the opinion of the investigator, unsafe for them to participate: inflammatory bowel disease (if currently active) or have had prior resection of small intestine; Heart disease (e.g., myocardial infarction, heart failure, arrhythmias or poorly controlled hypertension) 90 days prior to Screening; Active bleeding disorder 90 days prior to Screening; Malignant disease within the last 2 years.
* Patients with a hemoglobin level \< 10 g/dL at Screening or a level that, in the opinion of the investigator, makes it unsafe for the subject to participate.
* Subjects receiving any form of cysteamine medication through a gastric tube.
* Subjects who are receiving maintenance dialysis or who have had a kidney transplant.
* Subjects who are on an active kidney transplant list or who are planning to receive a kidney transplant within 3 months of Screening.
* Subjects with known hypersensitivity to cysteamine or penicillamine.
* Female subjects who are nursing, planning a pregnancy, known or suspected to be pregnant, or have a positive serum pregnancy screen.
* Subjects who have a made a blood donation within 30 days of Screening.
* Subjects who, in the opinion of the Investigator, are not able or willing to comply with the protocol.

Primary outcomes:
measure: The Steady-state White Blood Cell Cystine Levels of RP103 Compared to Cystagon®
timeFrame: 4 weeks after the last subject has completed the study
Secondary outcomes:
measure: Comparison of Cysteamine PK Profiles, Steady State Cmax, Between RP103 and Cystagon®.
timeFrame: 4 weeks after the last subject has completed the study
measure: Comparison of Cysteamine PK Profiles, Steady State Tmax, Between RP103 and Cystagon®.
timeFrame: 4 weeks after the last subject has completed the study
measure: Comparison of Cysteamine PK Profiles, AUC(0-t), Between RP103 and Cystagon®.
timeFrame: 6 hours post dosing for Cystagon®; 12 hours post dosing for RP103.
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University Medical School
state: California
city: Atlanta
country: United States
facility: Emory Children's Center
state: Georgia
city: Chicago
country: United States
facility: Ann & Robert H. Lurie Children's Hospital of Chicago (formerly Children's Memorial Hospital)
state: Illinois
city: Lyon
country: France
facility: Hospices Civils de Lyon
city: Montpellier
country: France
facility: Villeneuve-Lapeyronie Hospital
city: Paris
country: France
facility: Necker Hospital
city: Paris
country: France
facility: Robert Debre Hospital
city: Nijmegen
country: Netherlands
facility: Radboud University Nijmegen Medical Center
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References:
citation: Dohil R, Fidler M, Barshop BA, Gangoiti J, Deutsch R, Martin M, Schneider JA. Understanding intestinal cysteamine bitartrate absorption. J Pediatr. 2006 Jun;148(6):764-9. doi: 10.1016/j.jpeds.2006.01.050.
citation: Fidler MC, Barshop BA, Gangoiti JA, Deutsch R, Martin M, Schneider JA, Dohil R. Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion. Br J Clin Pharmacol. 2007 Jan;63(1):36-40. doi: 10.1111/j.1365-2125.2006.02734.x.
citation: Levtchenko EN, van Dael CM, de Graaf-Hess AC, Wilmer MJ, van den Heuvel LP, Monnens LA, Blom HJ. Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis. Pediatr Nephrol. 2006 Jan;21(1):110-3. doi: 10.1007/s00467-005-2052-0. Epub 2005 Oct 27.